Segmental Reporting

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Segment Reporting Disclosure

18.       SegmentReporting

Shire operates as one operating and reportable segment engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs.

For a more detailed description of segment disclosures about products, geographic areas and major customers, please read Note 23, SegmentalReporting, of the Shire 2015 Form 10-K.

In the periods set out below, revenues by major product were as follows:

	6 Months Ended June 30,
(in millions)	2016	2015
Product sales:
CINRYZE	$ 337.2	$ 286.9
ELAPRASE	277.6	271.5
FIRAZYR	265.0	196.6
REPLAGAL	221.6	214.4
VPRIV	171.6	171.1
KALBITOR	28.1	-
Genetic Diseases total	1,301.1	1,140.5
VYVANSE	1,026.9	841.6
ADDERALL XR	200.6	181.7
Other Neuroscience	57.8	52.4
Neuroscience total	1,285.3	1,075.7
LIALDA/MEZAVANT	361.7	306.4
PENTASA	136.9	145.0
GATTEX/REVESTIVE	96.2	52.2
NATPARA	35.5	5.9
Other Internal Medicine	173.3	173.7
Internal Medicine total	803.6	683.2
HEMOPHILIA	275.6	-
INHIBITOR THERAPIES	74.0	-
Hematology total	349.6	-
IMMUNOGLOBULIN THERAPIES	138.2	-
BIO THERAPEUTICS	51.3	-
Immunology total	189.5	-
Oncology total	20.3	-
Total product sales	3,949.4	2,899.4
Royalties and Other Revenues:
SENSIPAR Royalties	73.5	45.2
3TC and ZEFFIX Royalties	27.1	18.0
FOSRENOL Royalties	20.6	19.2
ADDERALL XR Royalties	11.0	15.1
Other Royalties and Revenues	56.8	49.1
Total Royalties and Other Revenues	189.0	146.6
Total Revenues	$ 4,138.4	$ 3,046.0